Developing long acting agonists and antagonists of glycoprotein hormones using gene fusion and gene transfer: From bench to clinics

Keyphrases

• Clinical Application 100%
• Growth Hormone 100%
• Gene-gene 100%
• Gene Transfer 100%
• Gene Fusion 100%
• Glycoprotein Hormone 100%
• Oligosaccharide Chains 100%
• Ligation 100%
• Novel Therapeutics 50%
• Biological Activity 50%
• Clinical Levels 50%
• Most Common Form 50%
• Short Lifetime 50%
• Dose Effect 50%
• Active Compounds 50%
• European Community 50%
• Thyrotropin 50%
• Thyroid Disease 50%
• Hyperthyroidism 50%
• Medical Applications 50%
• Phase Factor 50%
• Human Thyroid 50%
• N-linked Oligosaccharide 50%
• Thyroid Follicle 50%
• Follitropin 50%
• Chemical Techniques 50%
• Thyroid-stimulating Immunoglobulin 50%
• Stability Factor 50%
• Peptidase Inhibitors 50%
• Number of Injections 50%
• Erythropoietin 50%
• Rapid Clearance 50%
• Carboxyl 50%
• O-linked Oligosaccharides 50%
• Graves' Disease 50%
• New Analogs 50%
• Clinical Trial Phases 50%
• Stable Compounds 50%
• Clinical Trial Phase 3 50%
• Genetic Engineering Techniques 50%

Biochemistry, Genetics and Molecular Biology

• Agonist 100%
• Bovine Somatotropin 100%
• Growth Hormone 100%
• Clinical Trial 100%
• Transfer Gene 100%
• Gene Fusion 100%
• Oligosaccharide 100%
• Glycoprotein 100%
• Factor VII 100%
• Genetics 50%
• Lifespan 50%
• Biological Activity 50%
• Wild Type 50%
• Intravenous Immunoglobulin 50%
• Secretion (Process) 50%
• Cyclic Adenosine Monophosphate 50%
• Thyroid-Stimulating Hormone 50%
• Peptidase 50%
• Follicle-Stimulating Hormone 50%
• Erythropoietin 50%
• Chemical Procedures 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Clinical Trial 100%
• Oligosaccharide 100%
• Glycoprotein 100%
• Growth Hormone 100%
• Blood Clotting Factor 7 100%
• Disease 50%
• Biological Activity 50%
• Thyroid Disease 50%
• Hyperthyroidism 50%
• Thyrotropin 50%
• Follitropin 50%
• Thyroid Stimulating Immunoglobulin 50%
• Erythropoietin 50%
• Peptidase 50%
• Graves Disease 50%